ArticleFrontiers in oncology2025
Personalized preventive medicine using genomic information: future perspective and corresponding research plan.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized cancer screening guided by genomic information holds the potential for effective cancer prevention. However, current approaches face challenges, including the low risk associated with most genetic variants and limited experience in genetic counseling for healthy individuals. We are initiating a feasibility study that employs a germline cancer genomic panel of 30-80 high-risk cancer genes, such as BRCA1 and BRCA2, to identify individuals with pathogenic variants. Genetic counseling will be conducted by certified medical doctors and genetic counselors utilizing the Kanagawa Prospective "ME-BYO" Cohort Study. This initiative seeks to adapt hereditary cancer counseling practices to preventive medicine, addressing the differences in counseling between clinical and preventive settings. It aims to establish a framework for personalized cancer screening, contributing to future guidelines for identifying individuals at high risk of hereditary cancers. This research will help bridge the gap between genomic research and practical preventive medicine, paving the way for personalized cancer screening strategies based on genetic information.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.